86555-45-5Relevant articles and documents
Microwave-Assisted Ruthenium-Catalysed ortho-C?H Functionalization of N-Benzoyl α-Amino Ester Derivatives
Sharma, Nandini,Bahadur, Vijay,Sharma, Upendra K.,Saha, Debasmita,Li, Zhenghua,Kumar, Yogesh,Colaers, Jona,Singh, Brajendra K,Van der Eycken, Erik V.
supporting information, p. 3083 - 3089 (2018/08/24)
A microwave-assisted highly efficient intermolecular C?H functionalization sequence has been developed to access substituted isoquinolones using α-amino acid esters as a directing group. This methodology enables a wide range of N-benzoyl α-amino ester derivatives to react via a Ru-catalysed C?H bond activation sequence, to form isoquinolones with moderate to excellent yields. As an additional advantage, our strategy proved to be widely applicable and also enabled the reaction of alkenes to provide access to alkenylated benzamides. The methodology was also extended towards the synthesis of isoquinoline alkaloids derivatives viz. oxyavicine and a dipeptide. The developed protocol is simple and cheap, avoids tedious workup procedures and works efficiently under MW irradiation. (Figure presented.).
POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE
-
Paragraph 00150; 00151, (2017/11/03)
Compounds, compositions, and methods for the treatment of Canavan disease are described.
SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
-
Page/Page column 107, (2014/12/12)
Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.